NEWPORT BEACH, Calif.–(BUSINESS WIRE)– jCyte Inc., a biotech company dedicated to improving the
lives of patients with rare degenerative retinal diseases, announced today its Scientific Advisory Board (SAB)
comprised of world-renowned retinal physicians to provide external scientific review and high-level counsel on
the Company’s research and development programs.
The SAB will continue to work closely with the jCyte leadership team, as the Company advances the clinical
development of its investigational drug candidate jCell, a first-in-class investigational treatment for retinitis
pigmentosa, an inherited retinal disease.
“We are excited and privileged to have the opportunity to work with this group of retinal experts, on the
development of jCell in retinitis pigmentosa,” said Paul Bresge, Chief Executive Officer, jCyte, Inc. “These
thought-leaders bring tremendous understanding of retinal disorders, as well as extensive experience in drug
development from discovery through to late-stage clinical trials. We look forward to their continued
contributions as jCyte enters a new stage in advancing jCell’s clinical development.”
Members of the jCyte Scientific Advisory Board are as follows:
David S. Boyer, M.D. is a world-renowned clinician, surgeon, and educator at the Retina-Vitreous Associates
Medical Group in Southern California. He is board certified in ophthalmology and has completed formal subspecialty
training in medical and surgical diseases of the retina, vitreous, and macula. Dr. Boyer is currently a
leading investigator for various national clinical trials on retinal diseases and serves as an advisor for multiple
research, educational and charitable institutions. He received his medical degree from the Chicago Medical
School, finished his residency at the Los Angeles County – USC County Medical Center, and completed his
retinal surgery fellowship at the Wills Eye Hospital in Philadelphia. He is currently an Adjunct Clinical
Professor at USC/Keck School of Medicine.
Jeffrey Heier, M.D. is the Co-President and Medical Director, Director of the Vitreoretinal Service, and
Director of Retina Research at Ophthalmic Consultants of Boston. Dr. Heier is on the Executive Board of the
Retina Society, the Executive Committee of the American Society of Retina Specialists, is the Past President of
the New England Ophthalmological Society, and a member of the Macula Society. He is one of the leading
retinal clinical researchers, and is a scientific advisor to many biotechnical or pharmaceutical companies,
lectures nationally and internationally, and has authored numerous, peer-reviewed works. Dr. Heier received his
medical degree from Boston University, did an internship and residency at Fitzsimons Army Medical Center,
and vitreoretinal fellowship at OCB/Tufts School of Medicine. Dr. Heier served as a physician in a Combat
Support Hospital in the Persian Gulf War, where he was awarded a Bronze Star.
Peter K. Kaiser, M.D. is the Chaney Family Endowed Chair for Ophthalmology Research and a Professor of
Ophthalmology at the Cleveland Clinic Lerner College of Medicine. He graduated magna cum laude with
Highest Honors from Harvard College and magna cum laude from Harvard Medical School. He completed an
internal medicine internship at Massachusetts General Hospital, an ophthalmology residency at the
Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute before
joining the vitreoretinal department of the Cole Eye Institute at the Cleveland Clinic, Cleveland, Ohio. As a RO1
NIH-funded investigator, Dr. Kaiser leads a team involved in the evaluation of vascular biology in AMD and
diabetic retinopathy. He is director of the Cole Center for ocular Research and Evaluation (CORE). He is the
founder and director of the Digital Optical Coherence Tomography Reading Center (DOCTR).
Baruch D. Kuppermann, M.D., Ph.D. is the Roger F. Steinert Professor, Chair of the Department of
Ophthalmology, and Director of the Gavin Herbert Eye Institute at the University of California, Irvine. He also
holds a joint appointment with the Department of Biomedical Engineering at UC Irvine. After completing his
Ph.D. in neuroscience at the California Institute of Technology, Dr. Kuppermann went on to earn an M.D. at the
University of Miami, and completed fellowships in Retina at both St. Joseph’s, and at the University of
California, San Diego. Dr. Kuppermann is also co-director of the Center for Translational Vision Research at UC
Irvine, which is focused on developing new treatments for blinding retinal conditions. He has published over
200 peer-reviewed articles in the medical literature, and over 50 book chapters. He is also strongly involved in
clinical research, having served as principal investigator in many trials evaluating new drugs and technologies.
About jCyte, Inc.
jCyte, Inc. is a clinical-stage biotech company focused on developing jCell therapy for retinitis pigmentosa (RP)
and other degenerative retinal disorders. jCell is a first-in-class investigational treatment for retinitis pigmentosa,
an inherited retinal disease. The treatment is minimally-invasive and given as an intravitreal injection. There are
currently no FDA approved therapies for RP. The company is pioneering a new era of regenerative therapies to
treat patients with unmet medical need. For more information, visit www.jcyte.com